<DOC>
	<DOCNO>NCT00409630</DOCNO>
	<brief_summary>Subjects age 20-45 mild moderate asthma recruit . Following consent , subject undergo evaluation assure underlie metabolic bone disease . Individuals treat inhaled fluticasone low high dose , daily 3 month . Serum urine biochemical marker bone metabolism collect baseline monthly three month . Adherence study medication adverse event collect monthly interval . Differences fluticasone low high dose treat individual analyze group compare baseline value .</brief_summary>
	<brief_title>Inhaled Fluticasone Propionate : Effect Parameters Bone Metabolism Patients With Mild Moderate Asthma</brief_title>
	<detailed_description>This study prospective randomize trial . Thirty subject mild moderate asthma receive inhale fluticasone propionate . Fifteen patient receive low dose inhale fluticasone 88 mcg twice daily . Fifteen patient receive inhale fluticasone 440 mcg twice daily . The primary outcome biochemical marker bone turnover . These include 1 ) serum biochemical marker bone formation [ osteocalcin , bone specific alkaline phosphatase ( ALP ) procollagen I C-terminal propeptide ( PICP ) ] 2 ) marker bone resorption , serum collagen type 1 C-Telopeptide ( CTx ) urinary N-telopeptide ( NTx ) immunoreactive free deoxypyridinoline ( iFDpd ) ] . Secondary endpoint include , parathyroid hormone ( PTH ) , Urinary Calcium/creatinine , adverse event .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Before studyspecific procedure , appropriate informed consent must sign Male premenopausal female subject Age ≥ 20 year ≤ 45 year age Documented History Mild moderate Asthma define NHLBI guideline : Mild Intermittent FEV1 PEF &gt; /= 80 % predict , PEF variability &lt; 20 % . Mild persistent FEV1 PEF &gt; 80 % predict , PEF variability , &gt; /= 2030 % Moderate persistent FEV1 PEF &gt; 60 % &lt; 80 % predict , PEF variability &gt; 30 % Ambulatory status Smoking Current use inhale glucocorticoid therapy use within past 3 month . Current use leukotriene modifier and/or inhaled bronchodilator allow . Use oral glucocorticoid within past year . Pregnant breast feeding . Last menstrual period great 1 year ago Diabetes Mellitus type 1 2 Paget 's Disease , osteomalacia , hyperparathyroidism , renal osteodystrophy metabolic bone diseases History hyperthyroidism within 1 year randomization AST ALT &gt; 2x upper limit normal Serum creatinine great 2.0 mg/DL History cancer within previous 5 year , ( exception : excise superficial lesion , basal squamous cell carcinoma skin . The use thiazide diuretic anticonvulsant medication . Subject currently enrol receive investigational drug within 30 day prior randomization Use ( within 3 month randomization ) hormone , SERMS , calcitonin , PTH ( Forteo ) Use ( within 6 month randomization ) bisphosphonates , ( Fosamax , Actonel , Didronel ) , Vitamin D 50,000 iu Use ( within 12 month randomization ) corticosteroid and/or inhaled steroid , anticonvulsant . Topical intraarticular steroid allow except topical steroid apply area measurement skin thickness make ; ie . Use ( within 24 month randomization ) I.V . Zometa I.V . Aredia Subject disorder compromise ability subject give write consent and/or comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Asthma</keyword>
</DOC>